View Future GrowthGenolution 과거 순이익 실적과거 기준 점검 0/6Genolution 의 수입은 연평균 -77.6%의 비율로 감소해 온 반면, Life Sciences 산업은 연평균 4.1%의 비율로 감소했습니다. 매출은 연평균 62.9%의 비율로 감소해 왔습니다.핵심 정보-77.59%순이익 성장률-77.72%주당순이익(EPS) 성장률Life Sciences 산업 성장률53.72%매출 성장률-62.85%자기자본이익률-18.55%순이익률-123.80%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.모든 업데이트 보기Recent updates공시 • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea분석 기사 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...공시 • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).공시 • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.공시 • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.공시 • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.공시 • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.분석 기사 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.공시 • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering매출 및 비용 세부 내역Genolution가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A225220 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 259,404-11,6439,48147230 Sep 259,146-8,0599,96860930 Jun 258,767-10,2579,60393331 Mar 257,942-8,9398,6661,51331 Dec 247,136-6,8268,0741,67230 Sep 247,283-9,4427,6212,34730 Jun 247,662-6,7167,2162,55031 Mar 247,914-6,0797,1943,17931 Dec 239,761-5,5127,0763,08131 Dec 2238,08514,6028,7841,516양질의 수익: A225220 은(는) 현재 수익성이 없습니다.이익 마진 증가: A225220는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 A225220의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A225220의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A225220은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(-29.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A225220는 현재 수익성이 없으므로 자본 수익률이 음수(-18.55%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 03:57종가2026/05/20 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genolution Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.
공시 • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
분석 기사 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
공시 • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).
공시 • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.
Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
공시 • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.
공시 • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.
공시 • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.
분석 기사 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...
Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.
Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.
공시 • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering